Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,175.41 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Jul 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Johnson & Johnson vs. Eli Lilly and: Which Pharma Giant Stock Is a Better Buy in 2026? ↗

July 16, 2026

One generates steady cash flow with a lower valuation; the other is growing at 45% but carries higher leverage.

Via The Motley Fool

Healthcare Investing in 2026: iShares Global Healthcare ETF Outperforms Invesco Health Care ETF ↗

July 16, 2026

IXJ's market-cap weighting and international exposure delivered stronger five-year returns and lower volatility, while offering double the dividend yield.

Via The Motley Fool

Topics ETFs

Eli Lilly Trips Into Red-Hot Psychedelics Space With A Big Takeover ↗

July 16, 2026

Eli Lilly tripped into the psychedelics space Thursday with the up to $3.8 billion acquisition of AtaiBeckley.

Via Investor's Business Daily

Eli Lilly & Co. (NYSE:LLY) Passes Navellier’s High-Growth Screen on Strong Earnings and Sales Momentum ↗

July 14, 2026

Via Chartmill

Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH? ↗

July 16, 2026

IHE concentrates on giants such as Johnson & Johnson and Eli Lilly, while XPH spreads risk across 65 holdings with different volatility profiles.

Via The Motley Fool

Topics ETFs

Meta, Vistra, T. Rowe Price and a Health Care Stock on CNBC’s ‘Final Trades’ ↗

July 16, 2026

Bill Baruch chose Eli Lilly as his final trade, supported by Citigroup's analyst. Other experts recommended Vistra, Meta Platforms, and T. Rowe Price.

Via Benzinga

The Next Wave Of Peptides Could Be Here; What Does It Mean For Lilly, Novo? ↗

July 16, 2026

FDA advisors will debate the merits of seven peptides next week. The discussion could have an impact on Lilly and Novo.

Via Investor's Business Daily

AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Reported Eli Lilly Acquisition Talks (CORRECTED) ↗

July 16, 2026

AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.

Via Benzinga

If You Invested $1000 In Eli Lilly Stock 5 Years Ago, You Would Have This Much Today ↗

July 15, 2026

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 25.47% on an annualized basis producing an average annual return of 37.22%. Currently, Eli Lilly has a market capitalization of...

Via Benzinga

Why Vivosim Labs Shares Are Rocketing on Wednesday? ↗

July 15, 2026

VivoSim Labs shares climbed after receiving a $5 million Eli Lilly milestone payment and forecasting more than 500% revenue growth in FY2027.

Via Benzinga

3 Vanguard ETFs Poised to Outperform as the Market Shifts Beyond Big Tech ↗

July 15, 2026

With investors finally embracing market segments beyond technology, these three Vanguard ETFs are winning.

Via The Motley Fool

Topics ETFs

2 Beaten-Down GLP-1 Stocks to Buy on the Dip ↗

July 15, 2026

Don't wait until clinical milestones send their share prices soaring.

Via The Motley Fool

Can Biogen Score Another Win In Alzheimer's Disease? ↗

July 14, 2026

Biogen and Ionis said Tuesday their tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over 18 months.

Via Investor's Business Daily

Is This Disturbing Trend Bad News for Eli Lilly in the Billion-Dollar Obesity Drug Market? ↗

July 14, 2026

Eyes are on the rollout of Lilly's new weight loss pill.

Via The Motley Fool

Cathie Wood Bought $54 Million Worth Of SpaceX Stock Last Week ↗

July 13, 2026

Cathie Wood's ARK Invest was extremely active last week, adding SpaceX and Meta, while selling AMD and Robinhood stock.

Via Investor's Business Daily

Topics ETFs

Eli Lilly Stock in Focus as Company Presents New Kisunla Data at AAIC Following Wave of Analyst Upgrades ↗

July 13, 2026

Eli Lilly shares are in the spotlight Monday as the company presents new Kisunla data at the AAIC in London.

Via Benzinga

Here's How Much Eli Lilly's Weight-Loss Drugs Are Worth to Investors ↗

July 13, 2026

Two drugs now generate almost two-thirds of the pharmaceutical giant's revenue.

Via The Motley Fool

Which is Best for Investors: Healthcare Stability (XLV) or Biotech Growth (IBBQ)? ↗

July 11, 2026

IBBQ surged 54.5% in one year but carries deeper drawdowns. XLV offers broader diversification, lower costs, and double dividend yield for steadier returns.

Via The Motley Fool

Topics ETFs

Which is the Better Choice for Healthcare Investors? IYH or BBH? ↗

July 11, 2026

BBH delivered 33.6% returns but swung 39.9% lower; IYH's 100 holdings offer steadier performance with 1.2% dividend yield.

Via The Motley Fool

Topics ETFs

Nvidia CEO Jensen Huang Said AI's "Most Profound Impact Will Be in Life Sciences." Does This Bet on a Biotech Stock Prove He Means It? ↗

July 11, 2026

One small investment offers big benefits for Nvidia.

Via The Motley Fool

Topics Artificial Intelligence

3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026 ↗

July 11, 2026

This is the list for you if you are looking for dividend stocks with attractive yields and well-supported dividends.

Via The Motley Fool

Should You Buy Eli Lilly Stock? Here's My Honest Take. ↗

July 11, 2026

There are good reasons to invest in Lilly and to hold off.

Via The Motley Fool

History Says Doing This 1 Thing Will Score You an Investing Win -- Even After a Market Crash. ↗

July 11, 2026

It's something very simple.

Via The Motley Fool

Topics Artificial Intelligence Stocks

Is Pfizer on Track to Launch Its Next Lipitor -- This Time in the Weight-Loss Market? ↗

July 10, 2026

So far, Pfizer has been an also-ran in the GLP-1 race, but that could change if its long-acting weight-loss medication takes off.

Via The Motley Fool

IHE vs. IBB: Which iShares Healthcare ETF Is the Better Buy? ↗

July 10, 2026

Established pharmaceutical giants have delivered lower volatility and higher income than clinical-stage biotech exposure over the past five years.

Via The Motley Fool

Topics ETFs

Record Numbers of Americans Are on GLP-1 Drugs. That's Great News for This Stock. ↗

July 09, 2026

Eli Lilly makes the best-selling GLP-1 drug, and sales are accelerating.

Via The Motley Fool

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026? ↗

July 09, 2026

PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost.

Via The Motley Fool

Topics ETFs

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up? ↗

July 09, 2026

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

Via The Motley Fool

Topics ETFs

July 09, 2026

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...

Via StockStory

My Forever Portfolio: 5 Undervalued Stocks to Buy Now and Hold Forever ↗

July 08, 2026

Investing for the long-term requires a different strategy.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.